Citizens raised the firm's price target on Precigen to $11 from $9 and keeps an Outperform rating on the shares. The firm is impressed by the strength of the PAPZIMEOS launch, which reflects the strong clinical profile of the product, thorough commercial readiness activities and compelling launch execution, the analyst tells investors in a research note.
